Analyst Price Targets — IDYA
Latest News for IDYA
IDEAYA Biosciences (NASDAQ: IDYA) shared top-line results from its randomized phase II/III OptimUM-02 study evaluating darovasertib in combination with crizotinib as a frontline treatment for HLA-A2 negative metastatic uveal melanoma. The webcast featured prepared remarks from Founder, President, and CEO Yujiro S. Hata and Chief Medical Officer Darrin M. Beaupre, with clinical perspective during Q&A from
IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal Melanoma Transcript
IDEAYA shares rise after darovasertib trial shows progression-free survival benefit in uveal melanoma; NDA filing planned for 2026.
The California-based biotechnology company reports statistically significant results from a clinical trial evaluating its combination therapy for a rare eye cancer.
Trial met the primary endpoint showing statistically significant improvement in median PFS by BICR, with 6.9 months for the darovasertib combination versus 3.1 months for ICT (HR: 0.42; 95% CI: 0.30, 0.59; p-value: 10,000 patients globally (including North America, Europe and Australia) and >3,000 patients in the United States, with approximately 50% of patients progressing to metastatic disease (mUM). We estimate…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IDYA.
U.S. House Trading
No House trades found for IDYA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.